/
LQDA
$79.73+$4.61 (+6.14%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$7.0B
89M shares
52-week range
$11.85 – $80.69
99% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.26%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$76.91
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7M | $8.1M | $739.6K | $12.9M | $15.9M | $17.5M | $14.0M | $158.3M |
| Cost of revenue | $121.4K | $807.2K | $237.7K | $3.0M | $2.9M | $2.9M | $5.9M | $13.2M |
| Gross profit | $2.6M | $7.3M | $501.9K | $9.8M | $13.1M | $14.6M | $8.1M | $145.1M |
| Gross margin | 95.5% | 90.0% | 67.9% | 76.5% | 82.1% | 83.5% | 58.0% | 91.6% |
| R&D | $28.7M | $40.5M | $32.2M | $20.5M | $19.4M | $43.2M | $47.8M | $39.3M |
| Operating income | −$34.9M | −$46.8M | −$59.1M | −$33.8M | −$38.8M | −$73.4M | −$121.3M | −$51.4M |
| EBITDA | −$32.6M | −$43.4M | −$55.8M | −$28.2M | −$35.0M | −$70.1M | −$115.7M | −$43.2M |
| Net income | −$53.1M | −$47.6M | −$59.8M | −$34.6M | −$41.0M | −$78.5M | −$130.4M | −$68.9M |
| Net margin | -1962.9% | -589.5% | -8080.1% | -269.0% | -257.4% | -448.9% | -931.7% | -43.5% |
| EPS (diluted) | -7.42 | -2.51 | -1.76 | -0.70 | -0.67 | -1.21 | -1.66 | -0.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $722M | $3.30 | $2.62–$4.41 | 5 |
| 2027 | $1.2B | $5.65 | $4.70–$6.97 | 5 |
| 2028 | $1.3B | $6.18 | $5.42–$6.95 | 5 |
| 2029 | $1.5B | $6.71 | $4.98–$8.10 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Liquidia Corporation Common Stock
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
www.liquidia.com- Employees
- 216
- IPO / List date
- Jul 26, 2018
- HQ
- MORRISVILLE, NC
Held by traders on TradeandTell
No one on the platform currently holds LQDA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 8,100 | $305.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LQDA yet.
